Clinical Trial Update: Alglucosidase Alfa Temporary Access Program

View source ↗

Summary

The document notes that alglucosidase alfa has received approval for a temporary access program with marketing approval for Pompe disease and glygogen storage d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glycogen Storage Disease Type Ii
• Pompe Disease

Drugs mentioned

• Alglucosidase alfa (alglucosidase alfa)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Glycogen Storage Disease Type II (GSD-II), Pompe Disease (Late-Onset) | Status: APPROVED_FOR_MARKETING